Survival of patients discharged after acute myocardial infarction and evidence-based drug therapy

European Journal of Epidemiology

Volumn 22, Issue 3, 2007, Pages 145-149

  Gouya, Ghazaleh ^a   Reichardt, Berthold ^b   Ohrenberger, Gerald ^c   Wolzt, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Burgenländische Gebietskrankenkasse ^*  (Austria)

^c KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

Author keywords

Acute myocardial infarction; Epidemiology; Evidence based medication; Survival

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; TICLOPIDINE;

ADULT; AGED; ARTICLE; DATA BASE; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HEALTH INSURANCE; HEALTH PROGRAM; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHARMACY; PRESCRIPTION; PROSPECTIVE STUDY; REIMBURSEMENT; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; AUSTRIA; CARDIOVASCULAR AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT DISCHARGE; QUALITY ASSURANCE, HEALTH CARE; SURVIVAL ANALYSIS;

EID: 33947579629     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-006-9087-9     Document Type: Article

References (19)

1. McGovern PG, Jacobs DR Jr., Shahar E, et al. Trends in acute coronary heart disease mortality, morbidity, medical care from 1985 through 1997: The Minnesota heart survey. Circulation 2001; 104: 19-24.
2. Rosamond WD, Folsom AR, Chambless LE, Wang CH. Coronary heart disease trends in four United States communities. The Atherosclerosis Risk in Communities (ARIC) study 1987-1996. Int J Epidemiol 2001; 30(Suppl 1): S17-S22.
3. Kirchhoff M, Davidsen M, Bronnum-Hansen H, et al. Incidence of myocardial infarction in the Danish MONICA population 1982-1991. Int J Epidemiol 1999; 28: 211-218.
4. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353: 1547-1557.
5. STATISTIK Austria- Jahrbuch der Gesundheitsstatistik 2004. Available at www.statistik.at/neuerscheinungen//download/2006/gesundheit 2004.
6. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
7. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Br Med J 1998; 316: 1337-1343.
8. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752-760.
9. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta Blockade after myocardial infarction: systematic review, meta regression analysis. Br Med J 1999; 318: 1730-1737.
10. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 44: E1-E211.
11. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J 2003; 145: 438-444.
12. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidencebased medical therapy on mortality in patients with acute coronary syndromes. Circulation 2004; 109: 745-749.
13. Yan AT, Tan M, Fitchett D, et al. One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary Syndromes Registry). Am J Cardiol 2004; 94: 25-29.
14. Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002; 23: 1190-1201.
15. Steg PG, Goldberg RJ, Gore JM, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 2002; 90: 358-363.
16. Pedersen TR, Faergeman O, Kastelein JJ, et al. Highdose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: a randomized controlled trial. Jama 2005; 294: 2437-2445.
17. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. Jama 2001; 285: 711-1718.
18. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipidlowering therapy on early mortality after acute coronary syndromes: An observational study. Lancet 2001; 357: 1063-1068.
19. Barron HV, Michaels AD, Maynard C, Every NR. Use of angiotensin- converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: Data from the National Registry of Myocardial Infarction 2. J Am Coll Cardiol 1998; 32: 360-367.